Conatus Pharma’s liver drug succeeds in mid-stage study, shares soar

(Reuters) – Conatus Pharmaceuticals Inc said its experimental lead drug was more effective than a placebo in a mid-stage study in patients with a form of fatty liver disease. The drug, emricasan, was tested in 38 patients with non-alcoholic fatty liver disease, including s…

Source:Conatus Pharma’s liver drug succeeds in mid-stage study, shares soar